Table 5 Summary of study design of all orphan medicinal products (n = 59)
From: Clinical evidence for orphan medicinal products-a cause for concern?
| Â | Number of OMPs (%) (n = 59) |
|---|---|
Control arm | |
  At least one study with placebo or standard of care as control | 44 (74.6%) |
Randomization | |
  At least one study with random design | 46 (78.0%) |
Blinding | |
  At least one study with double blind design | 34 (57.6%) |